Ethinylestradiol-Drospirenone 24+4

  • Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision
Current status
European Commission final decision

Overview

On 19 April 2012, the European Medicines Agency completed an arbitration procedure for Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4. The Agency's Committee for Medicinal Products for Human Use (CHMP) had been asked to consider a proposed change to the marketing authorisations for these medicines to include a new indication for the treatment of moderate acne in women seeking oral contraception. The Committee concluded that the change to the marketing authorisations cannot be granted.

Key facts

About this medicine
Approved name
Ethinylestradiol-Drospirenone 24+4
International non-proprietary name (INN) or common name
  • ethinyl estradiol
  • drospirenone
Associated names
Yaz 24+4
About this procedure
Current status
European Commission final decision
Reference number
EMEA/H/A-6(12)/1313
Type
Article 6(12) referrals (prior to January 2010)

This type of referral was triggered for a medicine that had been authorised by mutual recognition or via the decentralised procedure when there was disagreement between Member States on a variation (type II). This referral has been replaced by Article 13 referrals.

Key dates and outcomes
CHMP opinion date
19/04/2012
EC decision date
06/07/2012

All documents

European Commission final decision

  • List item

    Questions and answers on Ethinylestradiol-Drospirenone 24+4 (ethinylestradiol / drospirenone, 0.02 mg/3 mg tablets) (PDF/76.79 KB)

    Adopted

    First published: 20/04/2012
    Last updated: 11/01/2013
    EMA/257547/2012 Rev.1

  • List item

    Ethinylestradiol-Drospirenone 24+4 Article-6(12) referral - Annex I (PDF/42.23 KB)


    First published: 11/01/2013
    Last updated: 11/01/2013

  • List item

    Ethinylestradiol-Drospirenone 24+4 Article-6(12) referral - Annex II (PDF/70.3 KB)


    First published: 11/01/2013
    Last updated: 11/01/2013

  • List item

    Ethinylestradiol-Drospirenone 24+4 Article-6(12) referral - Assessment report (PDF/211.2 KB)

    Adopted

    First published: 11/01/2013
    Last updated: 11/01/2013
    EMA/399943/2012

  • Description of documents published

    Please note that some of the listed documents apply only to certain procedures.

    • Overview - lay-language summary of the stage of the procedure
    • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
    • Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
    • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
    • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
    • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
    • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
    • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
    • Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
    • Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
    • Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
    • Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
    • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
    • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
    • Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

    Note that older documents may have different titles.

    How useful was this page?

    Add your rating